Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia

PURPOSE: Colony-stimulating factor-3 receptor (CSF3R)-T618I is a recurrent activating mutation in chronic neutrophilic leukemia (CNL) and to a lesser extent in atypical chronic myeloid leukemia (aCML) resulting in constitutive JAK-STAT signaling. We sought to evaluate safety and efficacy of the JAK1...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Oncol
Glavni autori: Dao, Kim-Hien T., Gotlib, Jason, Deininger, Michael M.N., Oh, Stephen T., Cortes, Jorge E., Collins, Robert H., Winton, Elliot F., Parker, Dana R., Lee, Hyunjung, Reister, Anna, Schultz, Savage, Samantha, Stevens, Brockett, Chase, Subbiah, Nan, Press, Richard D., Raess, Philipp W., Cascio, Michael, Dunlap, Jennifer, Chen, Yiyi, Degnin, Catherine, Maxson, Julia E., Tognon, Cristina E., Macey, Tara, Druker, Brian J., Tyner, Jeffrey W.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2020
Teme:
RAPID COMMUNICATIONS
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7106977/
https://ncbi.nlm.nih.gov/pubmed/31880950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00895
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items